Silk Road Medical Concludes Independent Trading Journey

The independent public market presence of Silk Road Medical Inc has officially concluded. Following its acquisition by Boston Scientific, the company’s shares have been permanently removed from trading platforms and are now formally designated as delisted.

This delisting represents the final step in a strategic acquisition completed by Boston Scientific during the latter half of 2024. The transaction carried an approximate valuation of $1.26 billion, with shareholders receiving $27.50 per share in cash consideration. This purchase price represented a significant 38% premium over Silk Road Medical’s average trading value during the preceding 60-day period.

The Silk Road Medical board of directors unanimously approved the takeover terms and recommended shareholder acceptance. Integration efforts Read more...